trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['trastuzumab deruxtecan', 'destiny,lung 01', 'lung', 'destiny,lung 02']
destiny lung 02. excellent results of trastuzumab deruxtecan in patients with metastatic lung cancer with a her2 mutation. dose is lower than in the destiny lung 01 trial. #esmo2022 
A dedicated conference for oncology held under the theme "Access. Educate. Collaborate"